AlphAIAlphAI — Financial news for AI agents
financialcontent.comSEP 93 min read$COO

CooperCompanies (NASDAQ:COO) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 16.8%

CooperCompanies (COO) reported Q2 CY2026 sales of $1.07B, flat year-on-year and below estimates. Full-year guidance was 1.5% below analysts' expectations. Non-GAAP EPS of $1.15 beat estimates by 2.7%. The stock dropped 16.8% post-earnings. CEO Al White highlighted record free cash flow and growth in fertility but noted inventory reductions impacted results.

Original reporting
financialcontent.com
Published Sep 9, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CooperCompanies (NASDAQ:COO) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 16.8% — source image
Source · financialcontent.com
Decision brief

The 30-second read

$COOBearishHigh
01

Why it matters

The earnings miss and lowered guidance are likely to drive short‑term price declines, though cash flow strength may limit the downside.

02

Market read

Mid‑cap healthcare stock with a significant post‑earnings price drop, relevant for traders focusing on earnings volatility.

03

What to watch

Strong non‑GAAP EPS beat and record free cash flow could support a rebound if guidance is revised upward.

Relevance 8/10Novelty 8/10Timing: post‑market after earnings release

Background

CooperCompanies operates in vision care and women's health, reporting mixed results with a revenue miss but EPS beat.

Company-level read

Ticker impact

$COOBearishHigh confidence
Context

CooperCompanies reported Q2 2026 revenue flat at $1.07B, missing estimates and its full-year guidance fell 1.5% below consensus, causing the stock to drop 16.8% after the release.

Expected impact

Further downside pressure in the near term as investors reassess growth outlook.

Evidence & confidence

The combination of flat revenue, a miss on sales estimates, and a lowered full‑year guidance is a material catalyst for a sizable price move.

Market effects

Sector

Healthcare device sector may see broader scrutiny on growth forecasts.

Regional

U.S. market sentiment could be dampened by the miss from a mid‑cap medical device name.

Global

Limited to investors tracking U.S. healthcare equities.

Counterpoint

What could challenge this read

If the company can turn inventory reductions into margin recovery, the stock may be oversold.

Key entities

  • Company
    CooperCompanies

    Medical device maker (NASDAQ: COO) reporting Q2 2026 results.

Read at source← All news

Related articles

SEP 10
$AEOHigh

Premarket movers: American Eagle, Shoe Carnival slide following results

U.S. stock futures were mixed ahead of inflation data. American Eagle (AEO) shares fell 11% after weak results and flat margin outlook. Shoe Carnival (SCVL) dropped 23.3% on disappointing Q2 results and lowered outlook. Cooper Companies (COO) tumbled 15.3% after a revenue miss and lowered guidance. Alumis (ALMS) rose 6.3% on positive drug data. Culp (CFI) surged 18.8% on strong Q1 results. Vince Holding (VNCE) gained 5.3% after Q2 results.

investing.com3 min
SEP 10
$COOHighAI 9/10

Why is Cooper Companies stock plunging 15% today?

Cooper Companies (COO) stock fell 15.3% to $53.76 in pre-market trading after reporting fiscal Q3 2026 revenue of $1.07B, missing estimates by $30M. Adjusted EPS of $1.15 beat expectations. The company cut Q4 guidance, citing inventory reduction headwinds. The board decided to retain CooperSurgical after a strategic review. Piper Sandler and Baird downgraded the stock, citing weak growth and margin prospects.

investing.com2 min
SEP 10
$COOMedAI 8/10

Cooper Companies Q3 Results Up, Cuts FY26 View, Retains CooperSurgical, Expands Buyback; Shares Down

CooperCompanies (COO) reported Q3 earnings up but cut its FY26 outlook, citing U.S. channel inventory reductions at CooperVision. The company will retain CooperSurgical and expand its share buyback program to $3B. Shares fell 14.07% in overnight trading. Q4 guidance includes adjusted EPS of $1.05-$1.09 and revenue of $1.057B-$1.080B. FY26 outlook revised to EPS of $4.51-$4.55 and revenue of $4.229B-$4.252B.

rttnews.com2 min
SEP 9
$COOHighAI 9/10

Why is Cooper Companies stock plunging today?

Cooper Companies (COO) stock fell 15.3% in after-hours trading to $53.80 after reporting fiscal Q3 2026 results and deciding not to sell its CooperSurgical unit. Non-GAAP EPS beat estimates at $1.15, while revenue grew 1% to $1.066 billion. The company issued cautious Q4 guidance and expanded its share repurchase program to $3 billion. The broader market had minimal impact on the stock's decline.

investing.com4 min